Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

Cardioxyl Pharmaceuticals (Chapel Hill, NC), a clinical stage pharmaceutical company utilizing its proprietary nitroxyl chemistry platform to discover and develop novel therapeutics to treat cardiovascular disease, closed a $28M Series B financing. Participants include OrbiMed Advisors, Osage University Partners, New Enterprise Associates and The Aurora Funds.

Heat Biologics (Chapel Hill, NC) a clinical-stage biopharmaceutical company focused on vaccines and antibodies for non-small cell lung cancer and stimulation of regulatory T cells, closed a $2.8M Series A financing. Participants include Brightline Ventures.

CeNeRx (Cary, NC) a clinical-stage biopharmaceutical company focused on diseases of the central nervous system, depression and anxiety, closed a $4.6M Series D financing. Participants include Aisling Capital, L Capital Partners, Perseus Soros Biopharmaceutical Fund, Omega Funds and Pappas Ventures.

Metabolon (Durham, NC) a commercial-stage provider of biomarker discovery and analysis, closed a $13.1M Series D financing. Participants include Keating Capital, Sevin Rosen Funds, Aurora Funds, Harris & Harris Group, Syngenta Ventures and Fletcher Spaght.

Clinipace Worldwide (Durham, NC) a commercial-stage global digital clinical research organization specializing in strategic product and clinical development, closed a $15M Series C financing. Participants include Morgan Stanley, Hatteras Venture Partners and Brook Private Equity Advisors. The 3Q11 OnBioVC Trend Analysis Will Be Available Next Monday 31 October

Advanced Animal Diagnostics (Durham, NC) a commercial-stage developer of farm animal diagnostics focused on the detection of mastitis in dairy cows, closed a $11M Series B financing. Participants include Intersouth Partners and Novartis Venture Funds.

Chimerix (Durham, NC) a clinical-stage pharma company developing broad spectrum antiviral agents focusing on CMV and BK viruria, closed a $45M Series F financing. Participants include Pappas Ventures, Morningside Group, Sanderling Ventures, Canaan Partners, Alta Partners, Asset Management Co., Frazier Healthcare Ventures and New Leaf Venture Partners.

nContact Surgical (Morisville, NC) a clinical-stage medical device company focused on minimally invasive hearth arrhythmias, closed a $16M Series D financing. Participants include Harbert Venture Partners, Intersouth Partners, Massey Burch, Tall Oaks Capital, Village Ventures, Finistere Ventures, Hippo Ventures and ZMV Associates.

Cardioxyl Pharmaceuticals (Chapel Hill, NC) a clinical-stage small molecule company focused on acute decompensated heart failure, closed a $15M Series C financing. Participants include Aurora Funds and New Enterprise Associates.

Tryton Medical (Durham, NC) a commercial-stage medical device company focused on stents designed to treat bifurcation lesions, closed a $20M Series D financing. Participants include PTV Sciences, RiverVest Venture Partners and Spray Venture Partners.

CeNeRx (Cary, NC) a clinical-stage biopharmaceutical company focused on diseases of the central nervous system, closed a $10M Series C, bringing the round total to $14M. Participants include Aisling Capital, L Capital Partners and Pappas Ventures.

Liquidia Technologies (Research Triangle Park, NC) a development-stage company focused on improving delivery of inhaled therapeutics and vaccines via nanoparticles with optimized characteristics for increased target specificity, closed a $5M Series C financing, bringing the total round to $25M. Participants include Canaan Partners, Pappas Ventures, New Enterprise Associates, Morningside, Firelake Capital and PPD

TearScience (Morrisville, NC) a clinical-stage medical device company focused on the treatment of chronic evaporative dry eye due to obstructive Meibomian Gland Dysfunction, closed a $44.5M Series C financing. Participants include Essex Woodlands Health Ventures, Investor Growth Capital, General Catalyst, De Novo Ventures, Spray Ventures and Quaker Bio Ventures.

« Previous Entries  Next Page »

to top of page...